Home › Companies › Viking Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Viking Therapeutics, Inc.’s Form 8-K, filed 2026-05-26 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Viking Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Viking Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: J. Matthew Singleton | 28,648,459 | -- | -- | 14,562,012 | 36,879,061 | Majority: yes |
| Elect Director: S. Kathryn Rouan, Ph.D. | 21,960,203 | -- | -- | 21,250,268 | 36,879,061 | Majority: yes |
| Proposal 2: . To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026: | 78,368,957 | 1,241,969 | 478,606 | -- | -- | Majority: yes |
| Proposal 3: . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement: | 30,045,938 | 12,763,135 | 401,396 | -- | 36,879,063 | Majority: yes |
Source: Viking Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-05-26 — read the filing on EDGAR.
Each item below shows how the 413 asset managers that disclosed a Viking Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Viking Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-05-19.
Combines 16 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
Viking Therapeutics, Inc.’s own tally for this item (“Proposal 3: . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 30,045,938 for, 12,763,135 against, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,105,643 outstanding shares: 26% for, 11% against (37% of the company cast a for/against vote).
The 406 asset managers below cast 70% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,890,593 | 48,855 | 0 | 0 | For |
| Vanguard | 10,045,294 | 475,156 | 2 | 0 | For |
| BlackRock | 1,259,931 | 2,158,634 | 0 | 0 | Against |
| American Century | 0 | 2,063,806 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 1,766,786 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 0 | 1,589,304 | 0 | 0 | Against |
| Charles Schwab | 1,426,806 | 0 | 0 | 0 | For |
| State Street | 875,390 | 10,862 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 822,250 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 0 | 654,294 | 0 | 0 | Against |
| Vestal Point Capital, LP | 0 | 583,407 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 0 | 444,781 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 394,919 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 372,352 | 0 | 0 | Against |
| Citadel | 349,253 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 0 | 336,101 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 330,100 | 0 | 0 | Against |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 0 | 330,100 | 0 | 0 | Against |
| JPMorgan | 312,778 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 312,187 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 294,943 | 0 | 0 | Against |
| Principal | 280,964 | 0 | 0 | 0 | For |
| DE Shaw | 0 | 278,647 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 265,442 | 0 | 0 | Against |
Showing the 25 largest of 406 asset managers. See all 406 in the interactive database.
Meeting held 2026-05-19.
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Viking Therapeutics, Inc.’s own tally for this item (“Proposal 2: . To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026:”): 78,368,957 for, 1,241,969 against, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,105,643 outstanding shares: 67% for, 1% against (69% of the company cast a for/against vote).
The 80 asset managers below cast 99.9% of the shares they voted on this item FOR (20,987,118 for, 8,219 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,652,260 | 2 | 0 | 0 | For |
| Fidelity | 6,062,750 | 0 | 0 | 0 | For |
| American Century | 937,561 | 0 | 0 | 0 | For |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 664,856 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 330,100 | 0 | 0 | 0 | For |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 280,964 | 0 | 0 | 0 | For |
| State Street | 190,515 | 8 | 0 | 0 | For |
| TIAA | 184,547 | 0 | 0 | 0 | For |
| Lincoln Financial | 147,262 | 0 | 0 | 0 | For |
| Jackson National | 114,206 | 0 | 0 | 0 | For |
| First Trust | 106,325 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 100,464 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 74,811 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 70,222 | 0 | 0 | 0 | For |
| Victory Capital | 69,566 | 0 | 0 | 0 | For |
| ProShares | 56,862 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 50,800 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 48,490 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 47,000 | 0 | 0 | 0 | For |
| RMB INVESTORS TRUST | 42,460 | 0 | 0 | 0 | For |
| Guggenheim | 33,569 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 31,034 | 0 | 0 | 0 | For |
Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.
Meeting held 2026-05-19.
Combines 8 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
Viking Therapeutics, Inc.’s own tally for this item (“Elect Director: J. Matthew Singleton”): 28,648,459 for, 14,562,012 withheld, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,105,643 outstanding shares: 25% for, 13% withheld (37% of the company cast a for/withheld vote).
The 77 asset managers below cast 100% of the shares they voted on this item FOR (13,684,557 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,645,405 | 0 | 6,858 | 0 | For |
| Fidelity | 1,700,563 | 0 | 4,362,187 | 0 | Abstain |
| American Century | 0 | 0 | 937,561 | 0 | Abstain |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 335,565 | 0 | 329,291 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 330,100 | 0 | Abstain |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 280,964 | 0 | Abstain |
| State Street | 190,298 | 0 | 225 | 0 | For |
| TIAA | 184,547 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 147,262 | 0 | Abstain |
| Jackson National | 53,776 | 0 | 60,430 | 0 | Abstain |
| First Trust | 0 | 0 | 106,325 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 100,464 | 0 | Abstain |
| BARON SELECT FUNDS | 0 | 0 | 74,811 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 5,873 | 0 | 64,349 | 0 | Abstain |
| Victory Capital | 0 | 0 | 69,566 | 0 | Abstain |
| ProShares | 0 | 0 | 56,862 | 0 | Abstain |
| WESMARK FUNDS | 0 | 0 | 50,800 | 0 | Abstain |
| Columbia Threadneedle | 48,490 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 0 | 0 | 47,000 | 0 | Abstain |
| RMB INVESTORS TRUST | 0 | 0 | 42,460 | 0 | Abstain |
| Guggenheim | 0 | 0 | 33,569 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 31,034 | 0 | Abstain |
Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.
Meeting held 2026-05-19.
Combines 9 wordings of this item as funds reported it.
50.8% Majority: yes · of votes cast
Viking Therapeutics, Inc.’s own tally for this item (“Elect Director: S. Kathryn Rouan, Ph.D.”): 21,960,203 for, 21,250,268 withheld, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,105,643 outstanding shares: 19% for, 18% withheld (37% of the company cast a for/withheld vote).
The 77 asset managers below cast 100% of the shares they voted on this item FOR (12,282,279 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,201,248 | 0 | 451,015 | 0 | For |
| Fidelity | 1,644,087 | 0 | 4,418,663 | 0 | Abstain |
| American Century | 0 | 0 | 937,561 | 0 | Abstain |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 664,856 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 330,100 | 0 | Abstain |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 280,964 | 0 | Abstain |
| State Street | 390 | 0 | 190,133 | 0 | Abstain |
| TIAA | 0 | 0 | 184,547 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 147,262 | 0 | Abstain |
| Jackson National | 0 | 0 | 114,206 | 0 | Abstain |
| First Trust | 0 | 0 | 106,325 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 100,464 | 0 | Abstain |
| BARON SELECT FUNDS | 0 | 0 | 74,811 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 70,222 | 0 | Abstain |
| Victory Capital | 0 | 0 | 69,566 | 0 | Abstain |
| ProShares | 0 | 0 | 56,862 | 0 | Abstain |
| WESMARK FUNDS | 0 | 0 | 50,800 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 48,490 | 0 | Abstain |
| Erste Asset Management GmbH | 0 | 0 | 47,000 | 0 | Abstain |
| RMB INVESTORS TRUST | 0 | 0 | 42,460 | 0 | Abstain |
| Guggenheim | 0 | 0 | 33,569 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 31,034 | 0 | Abstain |
Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.
Reported under meeting date 2026-03-20; no official results on file for that date.
Combines 2 wordings of this item as funds reported it.
0.1% fund support · no official result
The 2 asset managers below cast 0.1% of the shares they voted on this item FOR (1 for, 183,118 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0 | 183,118 | 0 | 0 | Against |
| Robertson Stephens Wealth Management, LLC | 1 | 0 | 0 | 0 | For |
Meeting held 2026-05-19.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,035 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BALLAST ADVISORS LLC | 1,000 | 0 | 0 | 0 | For |
| Roberts Wealth Advisors, LLC | 35 | 0 | 0 | 0 | For |
Meeting held 2026-05-19.
70% Majority: yes · of votes cast
Viking Therapeutics, Inc.’s own tally for this item (“Proposal 3: . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 30,045,938 for, 12,763,135 against, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,105,643 outstanding shares: 26% for, 11% against (37% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (158 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 158 | 0 | 0 | 0 | For |
| Ikarian Capital, LLC | 0 | 0 | 0 | 0 | -- |
Ranked by the number of Viking Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 116,105,643 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.42% |
| 2 | Vanguard | 9.06% |
| 3 | BlackRock | 2.94% |
| 4 | American Century | 1.78% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.52% |
| 6 | AMERIPRISE FINANCIAL INC | 1.37% |
| 7 | Charles Schwab | 1.23% |
| 8 | State Street | 0.76% |
| 9 | PNC BANK, NATIONAL ASSOCIATION | 0.71% |
| 10 | PICTET ASSET MANAGEMENT SA | 0.56% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 8.60% | 13F |
| BlackRock | 5.93% | 13F |
| FMR (Fidelity) | 5.19% | 13F |
| FMR LLC | 4.97% | DEF14A |
| Two Sigma | 3.82% | 13F |
| State Street | 3.79% | 13F |
| Brian Lian, Ph.D. | 3.57% | DEF14A |
| Morgan Stanley | 2.65% | 13F |
| Citadel Advisors | 2.25% | 13F |
| D.E. Shaw | 1.44% | 13F |
Percentages above are of 116,105,643 shares outstanding, as reported by Viking Therapeutics, Inc. on its Form 10-Q dated 2026-04-15 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Viking Therapeutics, Inc.’s 10-Q dated 2026-04-15. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Viking Therapeutics, Inc.'s shareholder meeting held 2026-05-19, in the 2025-2026 proxy season, 413 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,603 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 70% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Viking Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-26.
Viking Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).